Volitionrx LTD (VNRX) Financial Statements
Industry: In Vitro & In Vivo Diagnostic Substances
In fiscal 2025, Volitionrx reported revenue of $1.7M, up 40.0% from $1.2M the year before. Net income was -$23.4M (a -1352.2% net margin), or -$4.37 per diluted share. Operating margin was -1258.5%. Operating activities generated -$19.7M of cash, leaving -$19.8M of free cash flow. At fiscal year end, Volitionrx held $6.9M in total assets against $42.5M in total liabilities, including $1.1M of cash and equivalents.
Open the full interactive Volitionrx financials → Quarterly statements, key ratios, valuation history and price charts.
Volitionrx Key Stats
| Share Price | $0.18 |
|---|---|
| Market Cap | $1.6M |
| Revenue YoY Growth | +40.0% |
| 52-Week Range | $0.18 – $9.20 |
| Shares Outstanding | 52.7 million (basic, 2021 Q4) |
Volitionrx Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $13,433 | $90,035 | $306,392 | $775,302 | $1.2M | $1.7M |
| Operating Income | -$21.2M | -$28.3M | -$31.8M | -$36.0M | -$27.0M | -$21.7M |
| Pre-Tax Income | -$20.4M | -$27.0M | -$30.6M | -$35.7M | -$27.3M | -$23.4M |
| Net Income | -$20.4M | -$27.0M | -$30.6M | -$35.7M | -$27.3M | -$23.4M |
| Diluted EPS | -$9.00 | -$10.20 | — | — | -$6.20 | -$4.37 |
Volitionrx Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $627,277 | $447,034 | $985,076 | $398,657 |
| Net Income | -$5.4M | -$6.3M | -$6.7M | -$7.3M |
| Diluted EPS | -$1.00 | -$0.06 | -$0.97 | -$0.85 |
Volitionrx Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.4M | $20.6M | $10.9M | $20.7M | $3.3M | $1.1M |
| Current Assets | $20.3M | $22.0M | $12.2M | $21.9M | $4.1M | $2.1M |
| Total Assets | $26.2M | $27.5M | $18.3M | $28.0M | $9.4M | $6.9M |
| Current Liabilities | $6.2M | $6.5M | $17.4M | $31.8M | $7.8M | $12.2M |
| Total Long-Term Debt | $3.4M | $3.1M | $3.8M | $4.8M | $4.8M | $6.7M |
| Total Liabilities | $9.9M | $9.8M | $21.4M | $36.7M | $35.5M | $42.5M |
| Shareholders' Equity | $16.3M | $17.7M | -$3.1M | -$7.8M | -$24.9M | -$34.2M |
Volitionrx Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$16.5M | -$20.9M | -$15.3M | -$18.1M | -$25.9M | -$19.7M |
| Cash From Investing | -$1.6M | -$973,559 | -$1.6M | -$1.1M | -$573,852 | -$89,558 |
| Cash From Financing | $20.6M | $22.9M | $6.9M | $29.0M | $8.7M | $17.1M |
| Free Cash Flow | -$18.4M | -$21.8M | -$16.8M | -$19.1M | -$26.2M | -$19.8M |
Figures from Volitionrx's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Volitionrx financials page for every line item.
Volitionrx Company Profile
| Ticker | VNRX |
|---|---|
| Exchange | NYSE |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Headquarters | Henderson, Nevada |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000093314 |
Frequently Asked Questions
What was Volitionrx's revenue in fiscal 2025?
Volitionrx (VNRX) reported revenue of $1.7M for fiscal 2025.
What is Volitionrx's annual revenue history?
Volitionrx's annual revenue by fiscal year: 2020: $13,433; 2021: $90,035; 2022: $306,392; 2023: $775,302; 2024: $1.2M; 2025: $1.7M.
What was Volitionrx's net income in fiscal 2025?
Volitionrx reported net income of -$23.4M for fiscal 2025.
What was Volitionrx's earnings per share (EPS) in fiscal 2025?
Volitionrx's diluted EPS was -$4.37 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Volitionrx generate in fiscal 2025?
Volitionrx generated -$19.8M of free cash flow in fiscal 2025.
What was Volitionrx's revenue last quarter?
In its most recent reported quarter (2026 Q2), Volitionrx reported revenue of $398,657.
How much debt does Volitionrx have?
Volitionrx reported $6.7M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Volitionrx are outstanding?
Volitionrx reported a weighted average of 52.7 million basic shares outstanding in 2021 Q4.
What is Volitionrx's market cap?
Based on its latest closing price, Volitionrx (VNRX) has a market capitalization of about $1.6M.
When does Volitionrx's fiscal year end?
Volitionrx's fiscal year end, as registered with the SEC, is December 31.
Where is Volitionrx headquartered?
Volitionrx lists its business address in Henderson, Nevada in its SEC filings.
Volitionrx Competitors & Similar Companies
See all 15 In Vitro & In Vivo Diagnostic Substances companies →